EGFR and neoplasm: At the present time, international guidelines allow prescription of first-line EGFR-TKI therapy based only on LB in those patients for whom a surgical procedure or biopsy is infeasible, or the amount of tumor tissue is scarce (Rolfo et al. 2018).